Publications by authors named "Ingolf Griebsch"

Claim this Profile
T
The Impact of Intravesical Instillations on Quality of Life in Patients with Non-Muscle-Invasive Bladder Cancer: A Systematic Review.
Ingolf Griebsch, Sunil Shrestha, Yair Lotan, Chi-Fai Ng, Andrew Bottomley

Oncol Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SISAQOL-IMI consensus-based guidelines to design, analyse, interpret, and present patient-reported outcomes in cancer clinical trials.
Cecilie D Amdal, Ragnhild S Falk, Ahu Alanya, Michael Schlichting, Satrajit Roychoudhury, Ingolf Griebsch

Lancet Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Life after radical cystectomy: A mixed-methods targeted review of patient-reported quality of life following bladder removal.
Ingolf Griebsch, Kristian Juul, Andrew Bottomley, Roya Sherafat-Kazemzadeh, Jack Pemment

BJUI Compass· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validity, reliability, responsiveness, and clinically meaningful change threshold estimates of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16).
Nathan A Clarke, Brendon Wong, Rachael Lawrance, Anders Ingelgård, Ingolf Griebsch

J Patient Rep Outcomes· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a disease conceptual model of patient experience with metastatic colorectal cancer: identification of the most salient symptoms and impacts.
Isabelle Guillemin, Mahesh Darpelly, Brendon Wong, Anders Ingelgård, Ingolf Griebsch

J Cancer Surviv· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures.
Madeline Pe, Ahu Alanya, Ragnhild Sorum Falk, Cecilie Delphin Amdal, Kristin Bjordal, Ingolf Griebsch

Lancet Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Mixed-Methods Study to Better Measure Patient-Reported Pain and Fatigue in Soft Tissue Sarcoma.
Louise Barrett, Emma Elliott, Maarten Voorhaar, Anders Ingelgård, Ingolf Griebsch

Oncol Ther· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measuring the Patient Experience in Rare Disorders: Benefit of Pragmatic Mixed-Methods Research in NUT Carcinoma.
Anna Ciesluk, Maarten Voorhaar, Louise Barrett, Jessica Baldasaro, Ingolf Griebsch

Oncol Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding the Patient Experience in NUT Carcinoma: Qualitative Interviews with Patients and Caregivers to Develop a Conceptual Framework.
Farrah Pompilus, Anna Ciesluk, Patrick Marquis, Ingolf Griebsch, Maarten Voorhaar

Oncol Ther· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials.
Melanie Calvert, Madeleine King, Rebecca Mercieca-Bebber, Olalekan Aiyegbusi, Derek Kyte, Ingolf Griebsch

BMJ Open· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Network meta-analyses for EGFR mutation-positive non-small-cell lung cancer: systematic review and overview of methods and shortcomings.
Carl Samuelsen, Ingolf Griebsch

J Comp Eff Res· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations.
Lotte Westerink, Jelmer L J Nicolai, Carl Samuelsen, Hans J M Smit, Pieter E Postmus, Ingolf Griebsch

Eur J Health Econ· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What is an estimand & how does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials?
Rachael Lawrance, Evgeny Degtyarev, Philip Griffiths, Peter Trask, Helen Lau, Ingolf Griebsch

J Patient Rep Outcomes· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium.
Corneel Coens, Madeline Pe, Amylou C Dueck, Jeff Sloan, Ethan Basch, Ingolf Griebsch

Lancet Oncol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States.
Carl Samuelsen, Jonathan Lim, Amanda Golembesky, Sulena Shrestha, Li Wang, Ingolf Griebsch

J Med Econ· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses.
Heinz-Josef Lenz, Guillem Argiles, Takayuki Yoshino, Sara Lonardi, Alfredo Falcone, Ingolf Griebsch

Clin Colorectal Cancer· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA.
Jonathan Lim, Carl Samuelsen, Amanda Golembesky, Sulena Shrestha, Li Wang, Ingolf Griebsch

Future Oncol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials.
Andrew Bottomley, Madeline Pe, Jeff Sloan, Ethan Basch, Franck Bonnetain, Ingolf Griebsch

Clin Trials· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review.
Madeline Pe, Lien Dorme, Corneel Coens, Ethan Basch, Melanie Calvert, Ingolf Griebsch

Lancet Oncol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options.
Sanjay Popat, Anders Mellemgaard, Martin Reck, Claudia Hastedt, Ingolf Griebsch

Future Oncol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards.
Andrew Bottomley, Madeline Pe, Jeff Sloan, Ethan Basch, Franck Bonnetain, Ingolf Griebsch

Lancet Oncol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis.
Sanjay Popat, Anders Mellemgaard, Kyle Fahrbach, Alison Martin, Maria Rizzo, Ingolf Griebsch

Future Oncol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer.
Silvia Novello, Rolf Kaiser, Anders Mellemgaard, Jean-Yves Douillard, Sergey Orlov, Ingolf Griebsch

Eur J Cancer· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The humanistic burden of head and neck cancer: a systematic literature review.
Erika Wissinger, Ingolf Griebsch, Juliane Lungershausen, Michael Byrnes, Karin Travers

Pharmacoeconomics· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is progression-free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib.
Ingolf Griebsch, Michael Palmer, Peter M Fayers, Stuart Ellis

BMJ Open· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis